Unlike its parent molecule, Dihexa exhibits enhanced stability and improved bioavailability, allowing it to readily cross the blood-brain barrier and exert its therapeutic effects
Transepithelial transport can occur by energy-independent direct uptake or paracellular diffusion, and by energy-dependent endocytic pathways and transcytosis, receptor-aided transport, or carrier-medicated translocation (Kristensen and Nielsen, 2016)
Weight loss can reduce the risk of developing these health problems but, despite this, levels of obesity remain high
D.et al (2017)
glucagon suppression, lowering hepatic glucose output Central Nervous System: Decreases food intake by targeting homeostatic and hedonic appetite pathways (hindbrain/hypothalamus), reducing hunger and cravings, and enhancing satiety Gastrointestinal Tract: Delays gastric emptying, contributing to satiety (transient effect at higher doses) Adiposity/Energy Intake : Weight loss is primarily driven by sustained reduction in caloric intake, not increased energy expenditure Biological Activity Potent GLP-1 receptor agonist Enhances insulin secretion (glucose-dependent) Suppresses glucagon secretion Reduces appetite and caloric intake Produces significant, sustained body weight loss Improves cardiometabolic risk factors (glycemia, blood pressure, lipids) Storage Refrigerate once reconstituted
